Identification of SMYD2 as a candidate diagnostic and prognostic biomarker for gastric cancer.

ABSTRACT:

Background

Histone modification enzymes (HMEs) are associated with cancer development, treatment response, and prognosis. However, the potential roles of HMEs in gastric cancer (GC) remain unclear. This study aimed to investigate their biological functions and mechanisms in GC, with additional focus on exploring the clinical value of SMYD2.

Methods

We performed integrated analyses of transcriptome profiling and somatic mutation alteration in GC samples from the Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) datasets to characterize HMEs alterations in GC. Consensus unsupervised clustering analysis was performed to identify HMEs-associated GC subtypes. Various machine learning methods were employed to construct an HMEs-based diagnostic model for GC. The area

SUBMITTER: Wang S 

PROVIDER: S-EPMC12328180 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature